Equine Rotavirus Study Guide

Overview and Clinical Importance

Equine rotavirus (ERV) is the most common cause of infectious diarrhea in foals worldwide and represents a high-yield topic for the NAVLE. This double-stranded RNA virus of the family Reoviridae causes significant morbidity on breeding farms, with up to 50% of foals contracting the virus and morbidity rates exceeding 70% during outbreaks. While mortality is typically low (less than 1% with appropriate treatment), the economic impact is substantial due to intensive supportive care requirements, labor costs, and biosecurity measures.

The virus primarily affects foals less than 6 months of age, with the most severe disease occurring in neonates under 2 weeks old. In 2021, a novel Equine Rotavirus Group B (ERVB) was identified in Kentucky, expanding our understanding beyond the traditionally recognized Group A rotaviruses (ERVA). This discovery has significant implications for diagnosis and prevention strategies.

Etiology and Classification

Viral Characteristics

Rotaviruses belong to the genus Rotavirus within the family Reoviridae. The name derives from the Latin word "rota" (wheel) due to the characteristic wheel-like appearance under electron microscopy. Key structural features include:

Equine Rotavirus Groups and Genotypes

Until 2021, Group A rotavirus (ERVA) was considered the only group affecting horses. The predominant circulating genotypes globally are G3P[12] and G14P[12]. The commercially available vaccine contains only the G3P[12] strain, providing partial cross-protection against G14P[12].

Group B rotavirus (ERVB) was identified in 2021 during severe neonatal foal diarrhea outbreaks in Central Kentucky. This novel virus shows greater than 96% protein sequence identity with ruminant Group B rotaviruses, suggesting possible cross-species transmission. Importantly, current ERVA vaccines do NOT provide protection against ERVB.

Epidemiology

Transmission

The primary transmission route is fecal-oral. Foals become infected by ingesting materials or licking surfaces contaminated with infected feces. Key transmission factors include:

• Extremely low infectious dose: Less than 100 viral particles can cause disease
• High viral shedding: Diarrheic foals shed up to 100 billion (10^12) particles per gram of feces
• Short incubation period: 12-24 hours from exposure to onset of clinical signs
• Prolonged environmental survival: Up to 9 months in the environment
• Fomite transmission: Via contaminated personnel, equipment, boots, and stall-cleaning tools
• Asymptomatic shedding: Adult horses and recovered foals can shed virus subclinically for up to 8 months

Age Distribution and Risk Factors

Pathophysiology

Rotavirus causes diarrhea through multiple mechanisms involving both malabsorptive and secretory pathways. Understanding the pathophysiology is essential for rational treatment approaches.

Mechanism of Intestinal Damage

Step 1 - Viral Entry and Replication:

The virus targets mature enterocytes at the tips of the small intestinal villi (primarily duodenum and jejunum). VP4 protein attaches to cellular receptors (sialoglycoprotein and integrins), facilitating viral entry. The virus hijacks cellular machinery, multiplies rapidly within 10-12 hours, and releases into the intestinal lumen as the cell ruptures.

Step 2 - Villous Atrophy:

Destruction of mature villous tip enterocytes leads to villous blunting and atrophy. This results in marked reduction of the intestinal absorptive surface area. The crypt cells (immature secretory cells) are NOT affected by the virus, so they continue to proliferate, creating an imbalance between secretory crypts and absorptive villi.

Step 3 - Lactase Deficiency and Osmotic Diarrhea:

The destroyed villous tip cells are the primary site of lactase production. Loss of these cells results in transient lactose intolerance. Undigested lactose passes into the large intestine where bacterial fermentation produces short-chain fatty acids and gases, creating an osmotic gradient that draws water into the intestinal lumen.

Step 4 - NSP4 Enterotoxin Activity:

The viral non-structural protein NSP4 acts as an enterotoxin, triggering calcium-dependent chloride secretion via phospholipase C signaling. This causes secretory diarrhea independent of the malabsorptive mechanism. NSP4 also disrupts tight junctions between enterocytes, leading to paracellular fluid leakage.

Clinical Signs

Clinical presentation varies with age and immune status. The classic presentation involves sudden onset of signs 12-24 hours post-exposure.

Primary Clinical Signs

Potential Complications

• Gastric ulceration: Significant risk factor in diarrheic foals; stress-related and due to altered gut motility
• Septicemia/Bacteremia: Risk of bacterial translocation across compromised gut barrier; up to 50% of hospitalized foals with diarrhea have bacteremia
• Septic arthritis: Secondary to bacteremia; emphasizes need for prophylactic antibiotics in young foals
• Perianal scalding: From constant exposure to caustic diarrheic feces; requires attentive nursing care
• Pyloric/duodenal stenosis: Rare but serious complication

Diagnosis

Diagnosis is based on clinical presentation combined with laboratory confirmation. Because clinical signs are non-specific, laboratory testing is essential for definitive diagnosis.

Diagnostic Methods

Sample Collection Guidelines

• Collect fresh fecal sample (1-3 grams) or fecal swab early in disease course
• Sample multiple foals during outbreaks to improve detection rate
• ONE negative test is NOT conclusive - minimum of THREE consecutive negative tests needed to exclude rotavirus
• Watery stool may be dilute; collect adequate sample volume

Differential Diagnosis

Always submit additional samples to rule out other causes of foal diarrhea, as coinfections can occur.

Treatment

Treatment is primarily supportive since rotavirus infection is self-limiting. The goals are to maintain hydration, correct electrolyte imbalances, prevent secondary complications, and support the foal until intestinal healing occurs (7-14 days).

Treatment Protocol

Prevention

Vaccination Protocol

An inactivated killed vaccine (Zoetis) containing the G3P[12] strain is available for pregnant mares to provide passive transfer of antibodies via colostrum.

Biosecurity Measures

Strict biosecurity is essential for outbreak prevention and control.

Effective Disinfectants

• Peroxygen compounds: Virkon-S, Rescue (accelerated hydrogen peroxide)
• Phenolic compounds: One Stroke Environ, Pheno-Tek II, TekTrol
• Aldehydes: Effective but more toxic
• Iodine-based compounds: Effective

Ineffective Disinfectants

• Bleach (sodium hypochlorite): Inactivated by organic matter; ineffective in typical barn environments
• Quaternary ammonium compounds: Generally ineffective against rotavirus
• Chlorhexidine: Not reliably effective

Outbreak Management Protocol

• ISOLATE: Immediately separate affected foals and their dams; ideally keep in original stall or designated isolation facility
• PPE: Disposable gloves, dedicated coveralls/boots for each affected animal; wash hands before and after handling
• Foot dips: Place outside stalls containing sick foals; use effective disinfectant; replace frequently
• Dedicated equipment: Use separate stall-cleaning tools for affected foals; disinfect all equipment
• Manure management: DO NOT spread manure from infected horses on pastures
• Stall cleaning: Remove all organic material, wash with detergent, then disinfect; dirt floors may require removal of top layers
• Quarantine new arrivals: Isolate for at least 7 days before introduction to resident population

Memory Aid - "ROTAVIRUS" Prevention: Restrict access to affected foals | Outfit staff in dedicated PPE | Three doses for pregnant mares (8-9-10 months) | Avoid bleach - use peroxygen/phenolic | Vaccinate every pregnancy | Isolate immediately | Remove manure carefully | Use foot dips | Separate equipment

Prognosis

Prognosis is generally GOOD with appropriate supportive care. Survival rates exceed 94% at referral centers. Key prognostic factors include:

• Age: Foals less than 2 weeks old are at highest risk of mortality
• Promptness of treatment: Early intervention significantly improves outcomes
• Concurrent gastric ulceration: Associated with higher mortality risk
• Maternal vaccination status: Foals from vaccinated mares typically have milder disease

Resolution of clinical signs typically occurs within 3-5 days with supportive therapy. Full intestinal recovery takes 7-14 days. Recurrence after recovery is uncommon.